POSEIDA THERAPEUTICS INC's ticker is PSTX and the CUSIP is 73730P108. A total of 86 filers reported holding POSEIDA THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.13 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,482,975 | +35.2% | 1,043,267 | 0.0% | 1.02% | +13.8% |
| Q2 2023 | $1,836,150 | -42.9% | 1,043,267 | 0.0% | 0.90% | -41.8% |
| Q1 2023 | $3,213,262 | -41.9% | 1,043,267 | 0.0% | 1.55% | -57.6% |
| Q4 2022 | $5,529,315 | +50.1% | 1,043,267 | 0.0% | 3.65% | +49.2% |
| Q3 2022 | $3,683,000 | +36.8% | 1,043,267 | 0.0% | 2.45% | +27.3% |
| Q2 2022 | $2,692,000 | -42.4% | 1,043,267 | 0.0% | 1.92% | -23.8% |
| Q1 2022 | $4,674,000 | -34.2% | 1,043,267 | 0.0% | 2.52% | +0.6% |
| Q4 2021 | $7,105,000 | -6.6% | 1,043,267 | 0.0% | 2.51% | +65.3% |
| Q3 2021 | $7,605,000 | -27.3% | 1,043,267 | 0.0% | 1.52% | -9.4% |
| Q2 2021 | $10,454,000 | +4.9% | 1,043,267 | 0.0% | 1.67% | -6.6% |
| Q1 2021 | $9,963,000 | -12.9% | 1,043,267 | 0.0% | 1.79% | -8.8% |
| Q4 2020 | $11,445,000 | +23.7% | 1,043,267 | 0.0% | 1.96% | -33.5% |
| Q3 2020 | $9,254,000 | – | 1,043,267 | – | 2.96% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 1,043,267 | $7,605,000 | 1.52% |
| Privium Fund Management (UK) Ltd | 48,470 | $353,000 | 0.38% |
| Pentwater Capital Management LP | 4,967,227 | $36,211,000 | 0.37% |
| J. Goldman & Co LP | 301,391 | $2,197,000 | 0.11% |
| Perceptive Advisors | 787,745 | $5,743,000 | 0.08% |
| KNOTT DAVID M | 29,566 | $216,000 | 0.08% |
| Virtus ETF Advisers LLC | 23,082 | $168,000 | 0.07% |
| Altium Capital Management LP | 32,238 | $235,000 | 0.06% |
| Advisory Services Network, LLC | 268,290 | $1,956,000 | 0.06% |
| MCF Advisors LLC | 66,185 | $482,000 | 0.05% |